



Science Report 2012

Profil, Neuss, Germany

Summary

Cumulative Impact Factor	
Profil Author first/last Position	ΣIF_{2011} : 28,647
Profil Author first/last Position and Study performed in Neuss	ΣIF_{2011} : 18,588
Scientific Publications	
Original Articles	27 (ΣIF_{2011} : 110,935)
Reviews	4 (ΣIF_{2011} : -)
Cumulative Impact Factor	110,935
Book Chapters	1
Scientific Congress Presentations	
Oral Presentations	31
Poster Presentations	27
Advanced Training Courses	
Science Sessions	2
Trainings with External Participants	3
Granted Research Projects	6
Awards & Appointments	5

Scientific Publications

Original Articles

1. Arnolds S, Heckermann S, Koch C, Heissmann N, Sawicki PT How do patients' preferences compare to the present spectrum of diabetes research? **Exp Clin Endocrinol Diabetes** 10.1055/s-0032-1323776 [doi], 2012 IF: 1,693
2. Barkai L, Gurieva I, Stirban A, Tesfaye S, Czupryniak L, Mankovsky BN, Spallone V, IA Veresiu IA, Schnell O, Kempler P Microvascular complications in children and adolescents with type 1 diabetes. **Diabetes, Stoffwechsel und Herz** 21: 309-315, 2012, IF: -
3. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T, Becker RH Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and suprathreshold doses of glargine in subjects with type 1 diabetes. **Diabetes Care** dc12-0270 [pii];10.2337/dc12-0270 [doi] IF₂₀₁₁: 8,100
4. Buehlmeier J, Frings-Meuthen P, Remer T, Maser-Gluth C, Stehle P, Biolo G, Heer M Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: Results of a randomized controlled trial. **Clin Endocrinol Metab** doi:10.1210/jc.2012-2857, 2012 IF₂₀₁₁: 5,967
5. Caduff A, Heinemann L, Talary MS, Di Benedetto G, Lutz HU, Theander S A 4-h hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects **Acta Diabetologica** 49(5):333-339, 2012 IF₂₀₁₀: 2,784
6. Facchinetti A, Sparacino G, Guerra S, Luijf.M, Devries JH, Mader JK, Ellmerer M, Benesch C, Heinemann L, Bruttomesso D, Avogaro A, Cobelli C. Real-time improvement of continuous glucose-monitoring accuracy: the smart sensor concept. **Diabetes Care** dc12-0736 [pii];10.2337/dc12-0736 [doi], 2012 IF₂₀₁₁: 8,100
7. Heise T; Merker L, Matthaer S Insulin degludec: Ein neues, ultra-langwirksames Basalinsulin. **Diabetes, Stoffwechsel und Herz** 21: 231-238, 2012 IF₂₀₁₁: -
8. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes **Diabetes Obes Metab** 14(10): 944-950, 2012 IF₂₀₁₁: 3,379
9. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. **Diabetes Obes Metab** 14(9): 959-964, 2012 IF₂₀₁₁: 3,379
10. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. **Diabetes Res Clin Pract** 97(2): 258-266, 2012 IF₂₀₁₁: 2,754
11. Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader JK, Devries JH Continuous Glucose Monitoring Accuracy Results Vary between Assessment at Home and Assessment at the Clinical Research Center. **J Diabetes Sci Technol** 6(5): 1003-1006, 2012 IF₂₀₁₁: -

12. McVey E, Hirsch L, Sutter DE, [Kapitza C](#), [Dellweg S](#), [Clair J](#), Rebrin K, Judge K, Pettis RJ Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion **J Diabetes Sci Technol** 6(4):743-754, 2012 IF₂₀₁₁: -
13. Meier, JJ, Pennartz, C, Schenker, N, Menge, BA, Schmidt, WE, [Heise T](#), [Kapitza, C](#), Veldhuis, JD Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy. **Diabetes Obes Metab** 10.1111/dom.12022 [doi], 2012 IF₂₀₁₁: 3,379
14. Morgan JL, Zwart SR, [Heer M](#), Ploutz-Snyder R, Ericson K, Smith SM Bone metabolism and nutritional status during 30-day head-down tilt bed rest. **J Appl Physiol** doi:10.1152/jappphysiol.01064, 2012, IF₂₀₁₁: 3,753
15. [Nosek L](#), [Roggen K](#), [Heinemann L](#), [Gottschalk C](#), Kaiser M, [Arnolds S](#), [Heise T](#) Insulin aspart has a shorter duration of action than human insulin over a wide dose-range **Diabetes Obes Metab** 15(1):77-83, 2013, IF₂₀₁₁: 3,379
16. [Nosek L](#), Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, [Fischer A](#), [Heise T](#) Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus. **Diabetes Obes Metab** 14(12):1137-1144, 2012, IF₂₀₁₁: 3,379
17. [Plum L](#), Lin HV, Aizawa K, Liu Y, Wardlaw SL, Accili D. InsR/FoxO1 signaling curtails hypothalamic POMC neuron number. **PLoS ONE** 7: e31487, 2012 IF₂₀₁₁: 4,092
18. Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, Dugi KA, [Heise T](#) Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. **Diabetes Ther** 3(1):10.1007/s13300-012-0010-y [doi] IF₂₀₁₁: -
19. Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, [Plum L](#), Arancio O, Accili D. FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. **Cell** 149: 131–26, 2012 IF₂₀₁₁: 32,403
20. Smith SM, [Heer M](#), Wang Z, Huntoon CL, Zwart SR Long-duration space flight and bed rest effects on testosterone and other steroids. **JCEM** 97(1):270-8, 2012 IF₂₀₁₁: 5,967
21. Smith SM, [Heer M](#), Shackelford L, Sibonga JD, Ploutz-Snyder L, Zwart SR Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry. **J Bone Miner Res** 27(9):1896-906, 2012 IF₂₀₁₁: 7,056
22. [Stirban A](#), [Dellweg S](#) Neue Methoden zur Diagnose mikrovaskulärer Komplikationen. **Diabetes Congress-Report** 5: 22-25, 2012 IF: -
23. [Stirban A](#), Nandreaan S, Kirana S, Götting C, Veresiu IA, Tschoepe D Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers. **Int J Vas Med** doi:10.1155/2012/968761, 2012, IF: -
24. Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, [Heise T](#), [Heinemann L](#), Roden M Schloot NC Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial) **PLoS One** 7(3):e33108, 2012 IF₂₀₁₁: 4,092
25. Thomas A, [Heinemann L](#) Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research

Foundation continuous glucose monitoring study. **J Diabetes Sci Technol** 6(3): 572-580, 2012
IF₂₀₁₀: -

26. Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S Continuous glucose monitoring: quality of hypoglycaemia detection **Diabetes Obes Metab** Sep 13 10.1111/dom.12001 [doi], 2012 IF₂₀₁₁: 3,379
27. Zwart SR, Gibson CR, Mader TH, Ericson K, Heer M, Smith SM Vision changes after spaceflight are related to alterations in folate- and vitamin B-12 dependent one-carbon metabolism. **J Nutr** 142(3): 427-31, 2012 IF₂₀₁₁: 3,900

Reviews

1. Heer M An analysis of the "effect of olibra: a 12-week randomized control trial and a review of earlier studies". **J Diabetes Sci Technol** 6(3): 709-11, 2012, IF₂₀₁₁: -
2. Tigges C, Heer M The second-meal effect: Can meal-skipping and nutrient composition of a meal affect postprandial blood glucose levels from a subsequent meal? **Diabet, Nutritje, Risk Cardiometaabolic** 3: 33-39, 2012, IF₂₀₁₁: -
3. Heise T, Merker L, Matthaei S Insulin degludec: Ein neues, ultralangwirksames Basalinsulin **Diabetes, Stoffwechsel und Herz** 4: 231-238, 2012 IF₂₀₁₁: -
4. Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A für die Arbeitsgruppe CGM der Arbeitsgemeinschaft Diabetologische Technologie der DDG (AGDT) Evidenz und Konsens für den klinischen Einsatz von CGM. **Diabetes, Stoffwechsel und Herz** 1: 32-47, 2012 IF₂₀₁₁: -

Book Chapters

1. Heinemann L Kapitel 4 Diabetes-Technologie, in Diabetes Update 2012: pages 1-37, 2012

Scientific Congress Presentations

Oral Presentations

5th International Conference on Advanced Technologies & Treatments for Diabetes, Barcelona, Spain, February 08 - 11, 2012

1. Benesch C Diabetes technologies – regulatory topics that need more focus in Europe: The German experience. 5th ATTD, ATTD 2012 yearbook, in press
2. Heinemann L New ways of insulin delivery. 5th ATTD, ATTD 2012 yearbook, in press
3. Heinemann L Continuous glucose monitoring: reimbursement across Europe. 5th ATTD, ATTD 2012 yearbook, in press
4. Schaupp L, Schaller R, Huber A, Korsatko S, Deller S, Brunner M, Berghofer A, O'Connell, Zijlstra E, Heise T, Pieber, TR Continuous blood glucose monitoring by combining intravenous microdialysis and ionic reference technique. 5th ATTD, ATTD 2012 yearbook, in press

2nd Italian Diabetes Technology Meeting, Turin, Italy, March 03, 2012

1. Heinemann L AP@home: halftime of a European artificial pancreas project. 2nd IDTM, 2012

American Diabetes Association´s 72th Scientific Sessions, Philadelphia, PA, June 8-11, 2012

1. DeVries JH, Avogaro A, Benesch C, Bruttomesso D, Caldwell K, Cobelli C, Doll W, Del Favero S, Heinemann L, Hovorka R, Leelarathna L, Luijff YM, Mader J, Magni L, Nodale M, Place J, Renard E, Toffanin C on behalf of the AP@home consortium Comparison of two closed loop algorithms to open loop control during 24 hours including three meals and an exercise challenge. **Diabetes** 61 (S1): 224–OR, 2012
2. Heinemann L SMBG in non-insulin treated patients: pro. 72th ADA, 2012
3. Heise T, Nosek L, Hövelmann U, Böttcher SG, Hastrup H, Haahr H Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect. **Diabetes** 61 (S1): 349–OR, 2012
4. Nosek L, Ibarra P, Bagate K, Cardot J-M, Owens D, Fischer A, Heise T Optimal timing of terbutaline release has the potential to prevent insulin-induced nocturnal hypoglycemia. **Diabetes** 61 (S1): 172–OR, 2012
5. Zijlstra E, Heise T, Künnecke W Performance of a microdialysis-based continuous glucose monitoring (CGM) system. **Diabetes** 61 (S1): 6–OR, 2012

47. Jahrestagung der Deutschen Diabetes-Gesellschaft, Stuttgart, Germany, June 16-19, 2012

1. Heinemann L Artifizielles Pankreas, Stand der Entwicklung. Symposium: Update: Diabetes-Technologie. 47. DDG, 2012

2. Heinemann L Diabetes-Technologie: Nur CGM and CSII? Symposium: Diabetes-Technologie in der Realität. 47. DDG, 2012
3. Heinemann L Kontinuierliches Glukosemonitoring – In Studien und in der Praxis. 47. DDG, 2012
4. Heise T, Hövelmann U, Nosek L, Wilhelm B Das ultra-langwirksame Basalinsulin Insulin degludec: Zweifach längere Halbwertszeit und flacheres pharmakokinetisches Profil als Insulinglargin. **Diabetologie & Stoffwechsel** 7: S01 FV-58, 2012 47. DDG, 2012
5. Heise T, Nosek L, Wilhelm B Das neue ultra-langwirksame Basalinsulin Insulin degludec: Flaches Wirkprofil mit gleichmäßiger Verteilung des blutzuckersenkenden Effekts bei Typ 2 Diabetes. **Diabetologie & Stoffwechsel** 7: S01 FV-59, 2012 47. DDG, 2012

Experimental Biology, San Diego, CA, USA, April 21–25, 2012

1. Zwart SR, Heer M, Smith SM Urinary acid excretion can predict changes in bone metabolism during space flight. EB 2012

Grand Rounds of the Diabetes Center, Ann Arbor, MI, USA, May 15, 2012

1. Stirban A Postprandial endothelial function in diabetes: between ecstasy and agony. Ann Arbor 2012

33rd Annual International Gravitational Physiology Meeting, Aberdeen, UK, June 18-22, 2012

1. Heer M Acid-base balance and the musculoskeletal system, 33rd ISGP, 2012
2. Boschmann M, Frings-Meuthen P, Klug L, Parreidt N, Mähler A, Bühlmeier J, Heer M Energy expenditure and muscle metabolism during medium-term bed rest, 33rd ISGP, 2012
3. Frings-Meuthen P, Boehme G, Rittweger J, Heer M Effects of potassium bicarbonate supplementation on calcium and bone metabolism during 21-days of bed rest, 33rd ISGP, 2012

Practical ways to Achieve Targets in Diabetes Care, Keystone, CO, USA, July 12 – 15, 2012

1. Heinemann L Need for better insulins and biosimilars. Keystone Conference, 2012
2. Heinemann L Strengths, weakness and performance issues with SMBG. Keystone Conference, 2012

8th IFAC Symposium on Biological and Medical Systems, Budapest, Hungary, August 29-31, 2012

1. Heinemann L AP@home: An European project to bring the Artificial Pancreas home. 8th BMS, 2012

48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany, October 01-05, 2012

1. Heinemann L Better control and availability of medical devices. IDF Europe Symposium at the 48th EASD, 2012

2. Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Heinemann L, Place J, Renard E, Scotton R, DeVries JH, AP@home consortium. Postprandial glucose control by catheter based pumps versus patch pumps and the influence of wear time. **Diabetologia** 55 (S1): S87 A196, 2012
3. Renard EM, DeVries JH, Hovorka R, Doll W, Heinemann L, Cobelli C, Magni L, Farret A, Luijf YM, Leelarathna L, Mader JK, Benesch C, Bruttomesso D, DiPalma F, Nodale M Time in hypoglycaemia in patients with type 1 diabetes is dramatically reduced when insulin infusion is driven by two closed-loop algorithms in a randomised clinical trial. **Diabetologia** 55 (S1): S86 A194, 2012
4. Stirban A Cardiovascular effects of benfotiamine. Advisory Board Meeting Diabetic Neuropathy – How to translate academic knowledge into clinical practice? The case of benfotiamine. Symposium at the 48th EASD, 2012

12th Diabetes Technology Meeting, Bethesda, MD, USA, November 08-10, 2012

1. Heinemann L Biosimilar insulins? 12th DTM: S27, 2012
2. Heise T Ultra-long-acting insulins: do we need them? 12th DTM: S28, 2012

Congress of the Romanian Diabetes Federation, Cluj-Napoca, Romania, November 08-10, 2012

1. Stirban A Non-invasive methods for the assessment of vascular function. RDF, 2012

15th Annual CDA/CSEM Professional Conference and Annual Meeting Vancouver, BC, Canada October 10-13, 2012

1. Heise T, Nosek L, Hövelmann U, Böttcher SG, Hastrup-Nielsen H, Boras D, Haahr HL Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect. **Can J Diabetes** 36 (5): S13, 2012

Poster Presentations

5th International Conference on Advanced Technologies & Treatments for Diabetes, Barcelona, Spain, February 08-11, 2012

1. Luijf Y, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader J, DeVries JH, AP@home Consortium Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. 5th ATTD, P142 ATTD 2012 yearbook, in press
2. McVey E, Sutter DE, Judge K, Dellweg S, Clair J, Kapitza C, Hirsch L, Rebrin K, Pettis RJ Intradermal pre-prandial delivery of insulin lispro provides more rapid onset and improved blood glucose excursions compared to subcutaneous delivery. 5th ATTD, P150 ATTD 2012 yearbook, in press
3. Zijlstra E, Hartlep M, Heise T, Künnecke W Continuous glucose monitoring (CGM): A new method using on-line microdialysis in blood. 5th ATTD, P277 ATTD 2012 yearbook, in press

Society for Endocrinology BES 2012, Harrogate, UK, March 19-22, 2012

1. Heise T, Hövelmann U, Nosek L, Böttcher SG, Granhall C, Haahr H Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine. BES 28 P188, 2012

Experimental Biology, San Diego, CA, USA, April 21–25, 2012

1. Heer M, Smith SM, Frings-Meuthen P, Zwart SR, Baecker N High protein intake improves insulin sensitivity but exacerbates bone resorption in immobility, EB 2012

American Diabetes Association's 72th Scientific Sessions, Philadelphia, PA, June 8-11, 2012

1. Becker RHA, Kapitza C, Stechl J, Ruus P, Msihid J Restitution of glucose disposition with lixisenatide in T2DM subjects. **Diabetes** 61 (S1): 1081–P, 2012
2. Becker RHA, Stechl J, Kapitza C, Msihid J Augmentation of 1st- phase insulin release with lixisenatide in non-diabetic subjects. **Diabetes** 61 (S1): 1149–P, 2012
3. Heise T, Howey DC, Sinha VP, Choi SL, Mace KF Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 dosed once-daily (QD) in patients with Type 2 Diabetes Mellitus (T2DM). **Diabetes** 61 (S1): 1000–P, 2012
4. Heise T, Nosek L, Coester H-V, Roepstorff C, Segel S, Lassota N, Haahr H Steady state is reached within two to three days of once daily administration of ultra-long acting insulin degludec. **Diabetes** 61 (S1): 1013–P, 2012
5. Nosek L, Coester H-V, Thomsen HF, Roepstorff C, Haahr H, Heise T Glucose-lowering effect of insulin degludec is independent of sub-cutaneous injection region. **Diabetes** 61 (S1): 899–P, 2012
6. Giessmann T, Heise T, Macha S, Mattheus M, Woerle HJ, Broedl UC Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM. **Diabetes** 61 (S1):2240–PO, 2012

48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany, October 01-05, 2012

1. Arnolds S, Heckermann S, Sawicki PT How do patients' preferences compare to the present spectrum of diabetes research? **Diabetologia** 55 (S1): S394 A961, 2012
2. Becker RH, Kapitza C, Stechl J, Ruus P, Msihid J Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes. **Diabetologia** 55 (S1): S335 A813, 2012
3. Coester HV, Heise T, Nosek L, Roepstorff C, Segel S, Lassota N, Haahr H Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. **Diabetologia** 55 (S1): S373 A909, 2012
4. Heise T, Howey DC, Sinha VP, Choi SL, Mace KF Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in patients with type 2 diabetes mellitus. **Diabetologia** 55 (S1): S375 A913, 2012
5. Hövelmann U, Heise T, Nosek L, Böttcher SG, Hastrup H, Haahr H Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect. **Diabetologia** 55 (S1): S374 A912, 2012
6. Kapitza C, Lynge J, Düring M, Jensen C Safety, tolerability, pharmacokinetics (PK) / pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. **Diabetologia** 55 (S1): S341 A826, 2012
7. Stechl J, Becker RH, Kapitza C, Msihid J Augmentation of first-phase insulin release with lixisenatide in non-diabetic subjects. **Diabetologia** 55 (S1): S336 A814, 2012
8. Topp BG, Geiser JS, Soon DK, Heise T, Michael MD, Jacober SJ, Beals JM, Sinha VP Effects of a novel PEGylated basal insulin, LY2605541, on hepatic glucose output and muscle glucose uptake: simulations based on data from euglycaemic clamp studies. **Diabetologia** 55 (S1): S376 A914, 2012
9. Zijlstra E, Heise T, Künnecke W Performance of a microdialysis-based continuous glucose monitoring (CGM) system. **Diabetologia** 55 (S1): S429 A1045, 2012

15th Annual CDA/CSEM Professional Conference and Annual Meeting, Vancouver, BC, Canada October 10-13, 2012

1. Nosek L, Coester HV, Thomsen HF, Roepstorff C, Haahr HL, Sin R, Heise T Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. **Can J Diabetes** 36 (5): S46-S47, 2012
2. Heise T, Nosek L, Coester HV, Roepstorff C, Segel S, Lassota N, Boras D, Haahr HL Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. **Can J Diabetes** 36 (5): S47, 2012

12th Diabetes Technology Meeting, Bethesda, MD, USA, November 08-10, 2012

1. Benesch C, Haensler J, Heise T ClampArt: improving the quality of glucose clamps with a novel, conformité européenne-marked device. 12th DTM: A10, 2012

2. Luijf YM, DeVries JH, Mader JK, Doll W, Place J, Renard E, Bruttomesso D, Filippi A, Benesch C, Heinemann L, Accuracy and reliability of current continuous glucose monitoring systems: a direct comparison. 12th DTM: A83, 2012
3. Schaller-Ammann R, Korsatko S, Binder B, O'Connell M, Krejci J, Porro G, Zijlstra E, Heise T, Pieber TR, Schaupp L Improved performance of continuous blood glucose monitoring using intravenous microdialysis and the enhanced ionic reference technique. 12th DTM: A123, 2012
4. Zijlstra E, Heise T, Künnecke W Performance of a microdialysis-based continuous glucose monitoring system for hospital care. 12th DTM: A160, 2012

American Society of Nephrology (ASN) Kidney Week, San Diego, CA, USA October 30 – November 04, 2012

1. Polidori D, Sha S, Rothenberg PS, Plum-Mörschel L, Heise T. Validation of a novel method to determine the renal threshold for glucose in untreated and canagliflozin-treated subjects with type 2 diabetes. **J Am Soc Nephrol** 23: 217A, 2012

Advanced Training Courses

Science Sessions

1. 18. January 2012
Aktuelle Entwicklungen in der kardiologischen Bildgebung
Dr. med Jan Balzer
Klinik für Kardiologie, Pneumologie und Angiologie, Heinrich Heine Universität Düsseldorf,
Germany
2. 10. October 2012
Pancreatic beta-cell dedifferentiation as mechanism of diabetic beta-cell failure
Dr. Chutima Noi Talchai
Columbia University New York, USA

Trainings with External Participants

1. **Methoden in der experimentellen Ernährungsforschung**
22. – 28. February 2012
Profil Neuss, Germany
Masterstudiengang Humanernährung Rheinische Friedrich-Wilhelms-Universität Bonn,
Germany
2. **DuET 2012 Düsseldorf Education on Trials**
30. – 31. Oktober 2012
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
Novo Nordisk, Region Europe A/S
3. **Profil – Glucose-Clamp-Technique Introduction Course**
20. November 2011
Dorthe Gybel Jensen, Henrik Jarlov, Shanti Cecilia Werther, Ona Kinduryte,
Liliana Cristina Hansen
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
Novo Nordisk Bagsvaerd, Denmark

Granted Research Projects

1. **AP@Home – Bringing the Artificial Pancreas Home**
EU Project 7th Framework Programme (further information: <http://www.apathome.eu/>)
2. **Clinical Application for Metabolic Profiling (EU-CLAMP)**
EU Project 7th Framework Programme (further information: <http://www.euclamp.eu/>)
3. **MICROLOOP – Automatisierte Blutzuckerkontrolle in der klinischen Behandlung: Entwicklung eines auf der Mikrodialysetechnik basierten geschlossenen Regelkreises**
BMBF Project MED-327-060
4. **Untersuchung zum Knochenstoffwechsel** anhand von ISS Experimenten, ESA Bed Rest Experimenten, und MARS500 Experimenten, Rheinische Friedrich-Wilhelms-Universität Bonn, BMWi, Projektträger Raumfahrt
5. **Untersuchungen zur Auswirkung der Nährstoffzusammensetzung/-Supplementation auf den Knochen- und Kohlenhydratstoffwechsel anhand folgender Einzel-Projekte,**
Toulouse-MTBR-Bettruhe-Experimente PROPEI und Bone Quality, Antarktisstation Concordia Projekt MONU, ISS-Experiment Pro K, Rheinische Friedrich-Wilhelms-Universität Bonn, BMWi, Projektträger Raumfahrt
6. **Virtual Liver Network**
BMBF Project, terminated Sep 2012, (further information: <http://www.virtual-liver.de/>)

Awards & Appointments

1. **Carsten Benesch's ClampArt team and further employees of Profil**
ClampArt is CE-marked and licensed for Use in Europe
2. **Martina Heer**
Appointed as President of the International Society for Gravitational Physiology
3. **Lutz Heinemann**
Artificial Pancreas Research Award of the Diabetes Technology Society
4. **Daniela Lamers**
Jühling-Doktorandenpreis 2012 of the Anna-Wunderlich-Ernst-Jühling-Stiftung
5. **Alin Stirban**
Board member of the Arbeitsgemeinschaft Diabetische Neuropathie der DDG
Funder member of the Romanian Society for Diabetic Neuropathy
Co-Editor-in Chief of the 3rd Issue of Diabet, Nutritje, Risc Cardiometabolic, the official Journal of the Romanian Diabetes Federation
Member of the Scientific Board of the Gesellschaft für Biofaktoren e.V.